bullish
AFT Pharmaceuticals - Growth in the face of a challenging environment
SUMMARY
AFT Pharmaceuticals recently reported its results for FY21. Operating revenue grew strongly by 7% year-on-year to NZ$113.1m, driven mainly by 11% growth in Australia, despite the impact of COVID-19 across the business (especially lower licensing income and higher costs, including freight). Reported group operating profit was NZ$10.7m compared to NZ$21.2m in the same period a year ago (NZ$11.4m if a one-time FY20 gain of NZ$9.8m is excluded). Importantly, AFT is guiding to operating profit of NZ$18–23m in FY21.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Edison Investment Research
Leading International Investment Research
Price Chart(Sign Up to Access)
- AFT Pharmaceuticals - Growth in the face of a challenging environment26 May 2021
x